Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Retained Earnings (2016 - 2025)

Agios Pharmaceuticals' Retained Earnings history spans 14 years, with the latest figure at -$561.7 million for Q4 2025.

  • For Q4 2025, Retained Earnings fell 277.18% year-over-year to -$561.7 million; the TTM value through Dec 2025 reached -$561.7 million, down 277.18%, while the annual FY2025 figure was -$561.7 million, 277.18% down from the prior year.
  • Retained Earnings reached -$561.7 million in Q4 2025 per AGIO's latest filing, down from -$453.7 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $30.8 million in Q1 2021 to a low of -$1.0 billion in Q2 2024.
  • Average Retained Earnings over 5 years is -$429.5 million, with a median of -$439.5 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: skyrocketed 101.98% in 2021, then tumbled 1181.15% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$238.8 million in 2021, then crashed by 97.09% to -$470.6 million in 2022, then crashed by 74.82% to -$822.6 million in 2023, then soared by 81.9% to -$148.9 million in 2024, then crashed by 277.18% to -$561.7 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Retained Earnings are -$561.7 million (Q4 2025), -$453.7 million (Q3 2025), and -$350.2 million (Q2 2025).